🔉 Did tinnitus loudness improve?
None shown.
No clinical tinnitus data from any regenerative program.
Hair-cell regeneration & inner-ear gene therapy for Tinnitus: What Does the Evidence Show?
Regenerative Medicine
Current evidence
Gene therapy is genuinely restoring hearing in deaf children — but nothing in the regenerative pipeline measures tinnitus yet.
Evidence strength: Weak (1/5) · Tier 3 — experimental/emerging · Evidence independence: Primarily sponsor-supported.
The long-horizon hope: regrow or repair the damaged inner-ear cells whose loss drives most tinnitus. Includes hair-cell regeneration drugs (FX-322 — failed), gene therapy (DB-OTO, AK-OTOF — succeeding, for congenital deafness), and neural-progenitor cell therapy (Rinri — first-in-human).
Did tinnitus loudness or distress improve?
🧠 Did tinnitus distress improve?
None shown.
Same.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
How strong is the evidence?
Scored for tinnitus specifically: 1/5 (no data), Tier 3 as a legitimate emerging field to watch.
What the studies found 2 tracked
FX-322 (regenerative hair-cell program): Phase 2b failure and program discontinuation
Frequency Therapeutics (company communications) · Company announcement / trade press · 2023 · N=142 (Phase 2b FX-322-208) · Phase 2b randomized placebo-controlled (hearing restoration)
FAILED: no statistically meaningful difference vs placebo on the primary (speech perception) or any secondary endpoint (Feb 2023). Program discontinued; company pivoted away from hearing.
Relevance to tinnitus is INDIRECT: FX-322 targeted hearing restoration, and no tinnitus outcome measure was found in any FX-322 publication or coverage reviewed (the published Phase 1b reported none) — claims that tinnitus was measured are unable-to-verify. The failure matters to the regenerative-medicine pipeline narrative, not to any tinnitus evidence rating.
Cilcare CIL001 tinnitus program (company-reported development)
Cilcare (company communications) · Company announcements / trade press · 2025 · N=— · Drug development program: intratympanic candidate targeting cochlear synaptopathy; Phase 1b/2a program advancing to Phase 2a in chronic tinnitus (US and Europe)
COMPANY-REPORTED ONLY: single intratympanic injection targeting cochlear synaptopathy; the company describes a Phase 2a in chronic tinnitus (2025–26); €40M Series A closed Dec 2024. No peer-reviewed efficacy data exist — every efficacy statement is unverified.
Tracked as pipeline intelligence, not evidence. Registry check (ClinicalTrials.gov, 19 October 2026): paliroden (CIL001) NCT07826507 is Phase 1/2, not yet recruiting (estimated start January 2027); adverse events are the primary outcome and speech-in-noise is among the secondary outcomes; no tinnitus measure was found among the registered outcomes.
What are the limitations?
- No published tinnitus efficacy data; where registered trials list tinnitus questionnaires, they are secondary measures (for example in sudden-hearing-loss trials of vesicles)
- FX-322's failure shows regeneration in adults is far harder than gene replacement in children
- Whether restoring input reverses established central tinnitus is an open question
Has the result been independently replicated?
None yet.
What should patients know about safety?
Safety evidence: Not yet assessed. DB-OTO: no therapy-related serious adverse events reported to date.
Is it available?
Regulatory status: Investigational (all programs). DB-OTO (Regeneron): 11 of 12 deaf children gained hearing, 3 to normal thresholds — NEJM 2025; congenital OTOF deafness, not tinnitus. FX-322/FX-345 discontinued Feb 2023 after Phase 2b failure. Rinri's Rincell-1 first-in-human approved by UK MHRA 2025.
Availability: Trials only (specific genetic deafness) · Europe: Trials only · Cost (approx.): N/A
Claim checks that mention this treatment
From Tinnitus Claims: Fact vs. Evidence, which checks popular claims against the research. It does not change this treatment’s evidence rating.
Evidence last reviewed: 2026-09-04 · Evidence included through: 2026-09-04 · Confidence: high. Open the interactive evidence profile · How we rate evidence.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.